Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUK6YM)

Drug Name

BAY1161909 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Dual specificity protein kinase TTK (MPS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BOS172722	DMU790L	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
CFI-402257	DMH701Q	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
Tricyclic isoxazoloquinazoline derivative 2	DMH4TY1	N. A.	N. A.	Patented	[5]
Tricyclic isoxazoloquinazoline derivative 4	DM8VIM4	N. A.	N. A.	Patented	[5]
Tricyclic isoxazoloquinazoline derivative 3	DML2PWF	N. A.	N. A.	Patented	[5]
2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One	DMDN12L	Discovery agent	N.A.	Investigative	[6]
GNE-7915	DMYWM56	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dual specificity protein kinase TTK (MPS1)	TTP7EGM	TTK_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040625)
2	National Cancer Institute Drug Dictionary (drug id 761238).
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132.
5	Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48.
6	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7	Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2014 Feb 13;57(3):921-36.